VeriChip Corporation (the "Company" or "VeriChip") (NASDAQ:CHIP), a provider of RFID systems for healthcare and patient-related needs, announced today that John D. Halamka, MD, MS, has joined the Company's Medical Advisory Board as well as the joint committee formed by VeriChip and Digital Angel Corporation to design and develop a working, implantable glucose microchip to determine glucose levels in the bodies of animals and humans. Dr. Halamka serves as the Chief Information Officer of Harvard Medical School, Chief Information Officer of Beth Israel Deaconess Medical Center, Chief Information Officer of the Harvard Clinical Research Institute, and an Associate Professor of Emergency Medicine at Harvard Medical School. Dr. Halamka also serves on other nationally recognized boards including Google's Health Advisory Council. He will serve as an unpaid advisor on privacy, security and standards issues, as well as strategy and future applications of the VeriChip RFID implantable microchip technology.

?Dr. Halamka, who was one of the first individuals to get a VeriMed microchip in his arm, is unquestionably a visionary in the health information technology arena. He is a proven advocate for patient safety and a champion for patient privacy related to new technologies,? stated Scott. R. Silverman, Chairman and Chief Executive Officer of VeriChip Corporation. ?We are proud to have someone of his stature join our Medical Advisory Board.?

Commenting on his appointment, Dr. Halamka noted, ?Each patient weighs the risks and benefits of receiving an implanted chip. It is critical that implanted chips adhere to industry standards and protect patient confidentiality. I look forward to advising VeriChip Corporation to ensure its technology continues to meet these requirements.?

VeriChip Corporation's Medical Advisory Board is a team of key thought leaders with diverse experience in clinical and academic medicine, as well as business development and corporate leadership. The Medical Advisory Board provides strategic advice to the Company in the areas of medical issues, clinical studies and product development.

About VeriChip

VeriChip, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. The Company recently began marketing its VeriMed(TM) Patient Identification System, a passive RFID system for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.

VeriChip is majority-owned by Applied Digital Solutions, Inc. (Nasdaq:ADSX), which also owns a majority position in Digital Angel Corporation (Amex:DOC). For more information on VeriChip, please call 1-800-970-2447, or email info@verichipcorp.com. Additional information can be found online at http://www.verichipcorp.com.

Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

For VeriChip Corporation, Delray Beach
CEOcast
Dan Schustack, 212-732-4300
or
VeriChip Corporation
Allison Tomek, 561-805-8008
atomek@adsx.com